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Abstract
Milk-alkali syndrome (MAS) is a severe and life-threatening complication of the treatment of hypoparathyroidism characterised by renal 
failure, metabolic alkalosis, and hypercalcaemia. The clinical course often begins abruptly and without prodromal symptoms. Although 
it is closely related to the doses of calcium carbonate and active vitamin D preparations, its occurrence does not depend on the duration 
of hypoparathyroidism treatment. Among other factors triggering MAS are drugs influencing the glomerular filtration rate (angiotensin 
receptor blockers, sartans, aldosterone receptor antagonists, thiazide diuretics), lack of adequate control measures during hypoparathy-
roidism treatment, changes in calcium carbonate supplementation, dehydration, a diet rich in pH-basic foods (i.e. vegetarian diet), and 
pregnancy. A higher calcium carbonate dose is directly associated with an increased risk of milk-alkali syndrome. In cases of high calcium 
demand it is necessary to control renal function and monitor the level of serum calcium frequently, aiming for the lower end of the refe­
rence range. If MAS is confirmed or there are alarming neurological symptoms suggestive of hypercalcaemia, immediate hospitalisation 
is required. Treatment of MAS involves discontinuing calcium and vitamin D supplementation and administering an intravenous infusion 
of normal saline solution to eliminate volume deficiencies and achieve forced diuresis while maintaining proper fluid balance. As soon 
as there is improvement in the clinical condition, it is necessary to begin treatment of comorbidities increasing the risk of renal failure or 
alkalosis (i.e. vomiting, diarrhoea). (Endokrynol Pol 2018; 69 (2): 200–204)
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Streszczenie
Zespół Burnetta (milk-alkali syndrome, MAS), cechujący się niewydolnością nerek, zasadowicą metaboliczną i hiperkalcemią, jest ciężkim 
i zagrażającym życiu powikłaniem leczenia niedoczynności przytarczyc. Przebieg kliniczny jest często nagły i niepoprzedzony żadnymi 
objawami prodromalnymi. Wystąpienie zespołu Burneta nie zależy od czasu leczenia niedoczynności przytarczyc, mimo że jest on ściśle 
związany ze stosowaną terapią, zwłaszcza wielkością dawki węglanu wapnia i aktywnych preparatów witaminy D. Jako czynniki wy-
wołujące zespół Burnetta wymienia się między innymi leki wpływające na filtrację kłębuszkową (inhibitory receptorów angiotensyny, 
sartany, antagoniści receptora aldosteronu, diuretyki tiazydowe), brak odpowiedniej rutynowej kontroli, zmiany suplementacji węglanu 
wapnia, odwodnienie, dietę bogatą w produkty o zasadowym pH (tj. dieta wegetariańska), ciążę itp. Większe dawki węglanu wapnia 
wiążą się bezpośrednio ze zwiększonym ryzykiem zespołu Burnetta. W przypadku wysokiego zapotrzebowania na wapń konieczne 
jest częstsze kontrolowanie czynności nerek i monitorowanie stężeń wapnia w surowicy; przy czym należy się starać utrzymać stężenie 
wapnia w górnym zakresie wartości prawidłowych. W przypadku potwierdzenia zespołu Burnetta lub jeśli występują alarmujące obja-
wy neurologiczne świadczące o hiperkalcemii, należy niezwłocznie skierować chorego do szpitala. Leczenie zespołu Burnetta obejmuje: 
zaprzestanie suplementacji wapnia i witaminy D, dożylną infuzję soli fizjologicznej w celu uzupełnienia niedoborów objętościowych oraz 
wywołanie wymuszonej diurezy przy jednoczesnym utrzymaniu odpowiedniego bilansu płynów. Kiedy tylko stan kliniczny chorego się 
poprawi, należy rozpocząć leczenie zaburzeń współistniejących zwiększających ryzyko niewydolności nerek lub zasadowicy (wymioty, 
biegunka).  (Endokrynol Pol 2018; 69 (2): 200–204)
Słowa kluczowe: zespół Burnetta, hiperkalcemia, niedoczynność przytarczyc, alkalizacja, hiperkalciuria, zespół mleczno-alkaliczny, zasadowica 
metaboliczna, niewydolność nerek, aktywna witamina D
Introduction
Treating patients suffering from symptomatic post-
operational hypoparathyroidism with active vitamin D 
metabolites, calcium carbonate supplements, and a strict 
low­phosphate diet is difficult. The goal is to achieve 
a clinically asymptomatic state, with particular care given 
to avoiding tetany seizures. Attempting to stabilise the 
calcium level at any cost [1], however, is not recommend-
ed since it may lead to severe complications, such as:
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 — calcifications in the brain, kidney, heart, and blood 
vessels;
 — hypercalciuria leading to nephrolithiasis;
 — milk-alkali syndrome — MAS.
Deposition of calcium phosphate in soft tissues, 
including the brain, is related to its chemical properties. 
Precipitation of calcium salts in the skin and subcuta-
neous tissues known as metastatic calcinosis cutis is, 
in our experience, caused by disturbances in calcium-
phosphate metabolism unrelated to the pathology of 
MAS. The risk of deposit formation in MAS is increased 
in patients requiring multiple calcium infusions to 
alleviate tetany attacks during hyperphosphataemia. 
Excessive supplementation of active vitamin D also 
increases the likelihood of calcium deposit formation 
because it increases the absorption of both calcium and 
phosphate. Chronic hyperphosphataemia is a known 
risk factor for premature death, especially in patients 
suffering from kidney failure [2]. In patients with appro-
priate kidney function, increased phosphate levels pre-
dispose to calcium-phosphate deposition in soft tissue, 
especially surrounding the basal ganglia. This is due to 
respond of PIT 1 [3] and PIT 2 [4, 5] sodium phosphate 
contransporters to increase phosphate level in serum. 
This leads to overload of Pi cells and begins a chronic 
salting-out process of hydroxyapatite crystals [6]. 
Analysis using the calcium phosphate product is not 
always helpful. Incidental calcaemia values in patients 
with hypoparathyroidism are low. Our own stud-
ies demonstrated a transient increase in the calcium 
phosphate product after solitary administration of high 
doses of calcium.
Calcium-Phosphate Product 
Ca × P
Reference Range < 55 mg2/dl2  
(< 4.4 mmol2/l2)
Hypercalciuria is a constant feature of hypopar-
athyroidism, even if calcium concentrations in the 
serum are within the reference range. Active vitamin 
D preparations prescribed to control the symptoms 
of hypoparathyroidism are often given in doses that 
significantly exceed the physiological level. Therefore, 
thiazide diuretics are used in some patients despite 
their yet undocumented effect on renal stone forma-
tion and other complications of hypoparathyroidism 
treatment. 
Milk-alkali syndrome — definition
In the past, milk-alkali syndrome (also referred to as 
calcium-alkali syndrome) was associated with exces-
sive use of sodium bicarbonate, calcium carbonate, 
sucralfate, milk, and cream in the treatment of peptic 
ulcer disease (PUD). MAS was diagnosed on the basis 
of the following triad of symptoms: metabolic alkalosis, 
hypercalcaemia, and renal failure. Early case descrip-
tions date back to the 1920s. In 1936 Cuthbert Cope 
described cases of hypermagnesaemia, hyperphospha-
taemia, hypercalcaemia, alkalosis, renal failure, and their 
close relationship to the complications of peptic ulcer 
treatment. He observed an improvement in kidney 
function after discontinuation of the treatment, which 
led him to conclude that the renal impairment had 
caused the illness. In 1949 Charles Burnett described 
cases of MAS in patients treated only with sodium car-
bonate, without calcium salts or milk. In his research he 
emphasised the fact that not all patients suffered from 
hyperphosphataemia and irreversible renal failure, and 
biochemical dysfunctions were often accompanied by 
calcium depositions in soft tissues. Presently it is be-
lieved that both scholars were describing the same dis-
ease at different stages. Some scientists still distinguish 
among three different types of MAS: acute (Cope’s), 
chronic (Burnett’s), and an intermediate sub­acute form. 
In certain cases the rate at which symptoms recede de-
termines the form of the disease: normalisation of renal 
function test values and calcium levels within a few days 
indicates the acute type, no improvement over several 
days despite appropriate treatment indicates a chronic 
nature of the disease, while the remaining, in-between 
forms indicate the sub-acute type.
In recent years the treatment of PUD has changed 
and MAS is now mostly recognised in:
 — post-menopausal women prescribed calcium car-
bonate and vitamin D supplements to prevent/treat 
osteoporosis;
 — pregnant women taking calcium supplements;
 — bulimic patients suffering from chronic alkalosis;
 — persons undergoing dialysis and treatment based 
on active vitamin D and calcium carbonate sup-
plementation (alkalising medications);
 — persons being treated for hypoparathyroidism or, 
less often, alleged hypoparathyroidism.
MAS pathomechanism in patients treated 
for hypoparathyroidism
The elevated calcium level present during the develop-
ment of MAS is caused by both excessive ingestion of 
calcium and its impaired process of elimination from 
the body.
There are a few critical elements controlling the 
absorption of calcium in the gastrointestinal tract: 
 — Active vitamin D (calcitriol) influences the expres-
sion of genes through its nuclear receptors, directly 
and indirectly increasing the absorption of calcium 
from the gastrointestinal tract. Therefore, excessive 
intake of the active form of vitamin D increases the 
risk of hypercalcaemia [7–10];
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 — Increased calcium intake, as well as alkalisation of in-
testinal content (buffering of gastric acid), increases 
the absorption of calcium from the gastrointestinal 
tract [11, 12];
 — Sodium and water loss due to diarrhoea reduces 
the intravascular volume, which in turn activates 
the renin-angiotensin-aldosterone system and 
stimulates alkalosis. A decrease in the glomerular 
filtration rate associated with intravascular volume 
depletion impedes the excretion of calcium and 
bicarbonates [9, 10, 13];
 — Stimulation of the calcium receptor (CaS-R) caused 
by an elevated calcium level in the blood reduces 
the sensitivity of aquaporin receptors to vasopressin. 
Excessive calcium ingestion causes hypercalcaemia, 
which activates the calcium receptor. This intensi-
fies diuresis and further reduces the volume of the 
vascular bed, leading to secondary activation of the 
renin­angiotensin­aldosterone system, and finally 
resulting in renal failure and decreased urinary 
calcium excretion [9, 10, 13];
 — Metabolic alkalosis activates adapting mechanisms 
such as releasing hydrons from the “bone buffer”. 
Normalisation of phosphate levels observed in hy-
poparathyroidism indicates the vital clinical role of 
bone metabolism in patients with MAS. Phosphate 
levels decrease in spite of significantly impaired re-
nal function. This could be explained by tricalcium 
phosphate synthesis in the bones. This process 
is accompanied by the release of hydrons, which 
neutralize the alkaline pH value [14].
The variety in pathogenic mechanisms of MAS 
development in patients suffering from hypoparathy-
roidism is partially dependent upon the occurrence of 
different triggering factors. The most common factors 
are:
 — dehydration and/or compromised renal function 
(i.e. diuretic use, nephrotoxic medications, contrast 
agents);
 — a plant-based vegan or vegetarian diet (increased 
tendency towards alkalisation of the body);
 — excessive treatment with active analogues of vitamin 
D and calcium carbonates, causing exaggerated 
normalisation of calcium levels in the serum;
 — parallel intake of medications affecting the glo-
merular filtration rate (i.e. angiotensin­converting 
enzyme inhibitors).
MAS clinical case study
A 45­year­old woman with symptomatic intractable 
postoperative hypoparathyroidism, not adhering 
to a low­phosphate diet, was being treated with 4 g 
of calcium carbonate, 1000 I.U. cholecalciferol, 1 µg 
alfacalcidol, magnesium supplements and, temporarily, 
aluminium salts. She was admitted to the emergency 
department after her routine measurement of serum 
calcium levels was markedly elevated. The patient had 
independently increased her calcium carbonate dose 
around her menstrual period. MAS-related hypercal-
caemia was diagnosed based on the clinical picture and 
results of additional tests (Table I, II).
Tetany treatment may mask MAS symptoms and 
delay diagnosis. Presenting symptoms may be similar 
to those characteristic of hypercalcaemic crises, such as:
 — apathy;
 — imbalance;
 — weakness;
 — constipation;
 — nausea;
 — abdominal pain.
The following are deviations in the biochemical 
analysis of patients with MAS:
 — hypercalcaemia;
 — decreased glomerular filtration rate (GFR);
 — normalisation of phosphataemia;
Table I. Follow-up blood tests during the treatment of 
hypoparathyroidism and sub-acute milk-alkali syndrome
Table I. Kontrolne badania krwi w trakcie leczenia chorego 
z niedoczynnością przytarczyc i podostrym zespołem Burnetta
Hypoparathyroidism Milk-alkali 
syndrome
Ca (2.15–2.6 mmol/l) 1.72 4.1
PO4 (0.81–1.5 mmol/l) 2.05 0.99
ALP (38–126 U/l) 103 449
Creatinine (0.5–1.3 mg/dl) 0.88 6.72
GFR (MDRD) (> 60) > 60 6.7
Ca — calcium; PO4 — phosphate; ALP — alkaline phosphatase; GFR (MDRD) 
— glomerular filtration rate according to the MDRD formula
Table II Bone turnover markers during sub-acute type MAS
Table II Markery obrotu kostnego w trakcie epizodu 
podostrego zespołu Burnetta
Milk-alkali syndrome
FGF 23 (20–50 pg/ml) 13.84
Pro-collagen 1N terminal (15–59) 240.9
Osteocalcin (11–43 ng/ml) 143.5
DXA L1-L4 Z score +6.9
DXA of the femoral neck Z score +3.6
DXA of the core of the radius Z score +1.5
FGF 23 — fibroblast growth factor; DXA — bone densitometry using double-
beam radiation; L1 — first lumbar vertebra; L4 — fourth lumbar vertebra
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 — late-onset metabolic alkalosis, probably related to 
the impairment of bone buffering mechanisms as 
well as the aggravation of renal dysfunction.
MAS prevention and monitoring 
The following measures help prevent the development 
of MAS and MAS-related complications in patients with 
hypoparathyroidism:
 — avoiding (if possible) exceeding the calcium car-
bonate dose limit of 10 g (approx. 5 g of elemental 
calcium);
 — prescribing active vitamin D (alfacalcidol or calci-
triol) in the lowest possible dose sufficient to control 
symptoms, but not enough to lead to normocal-
caemia;
 — aiming for reduction rather than elimination of 
symptoms during the treatment of hypoparathy-
roidism in order to normalise the serum calcium 
level;
 — recommending a low-phosphate diet based on 
avoiding processed and preserved foods;
 — restricting the use of compounds impairing phos-
phate absorption, such as magnesium or aluminium 
salts. Chronic treatment may lead to aluminium 
deposits in bones, causing bone damage and 
aluminium osteopathy. Moreover, depositions of 
aluminium salts in the central nervous system may 
disturb cognitive functions. [7, 8].
Due to the statistically rare occurrence of MAS, 
preventative measures are predominantly based upon 
empirical knowledge or expert recommendations, 
rather than on evidence­based medicine (EBM). They 
are as follows:
 — routine monitoring of calcium, phosphate, and 
creatinine levels in all patients requiring non-
physiological doses of vitamin D and calcium prepa-
rations. Monitoring only calcium and phosphate 
levels may delay diagnosis of MAS. The dosage of 
calcium supplementation may be aided by diurnal 
measurements of the urinary calcium excretion 
rate, as well as assessment of the calcium clearance 
ratio. Additionally, monitoring helps estimate renal 
function;
 — calcium level measurement 14 days after starting 
treatment or after changing the dosage of medica-
tions prescribed for hypoparathyroidism;
 —  calcium level measurement 14 days after prescribing 
medications influencing the GFR (thiazide diuretics, 
I­ACE, sartans, spironolactone);
 — avoiding dehydration through adequate fluid con-
sumption;
 — educating patients on issues related to dietary ad-
herence and the need for medical attention in case 
of temporary and/or transient recession of tetany 
symptoms;
 — frequent monitoring of vegetarian patients and 
patients following a diet rich in basic/alkaline foods;
 — sudden clinical improvement, especially in patients 
who have been suffering from chronic calcium 
deficiency (tetany seizures), should be followed by 
careful evaluation of the calcium-phosphate concen-
trations and renal function. It must be emphasised 
that the occurrence of MAS is not related to the 
duration of hypoparathyroidism, but rather to a yet 
unknown triggering factor [15];
 — temporary intake of parathyroid hormone analogue, 
mainly when prescribing oral medication, is not pos-
sible. High costs, unknown long-term complications, 
and intensification of tetany symptoms after the 
discontinuation of treatment are all disadvantages 
of this therapy [16];
 — cell suspension transplants from parathyroid 
glands often fail to restore correct calcium homeo-
stasis on a long-term basis. Observations indicated 
a positive influence of this method on phosphate 
homeostasis.
MAS treatment
Only the acute and sub-acute forms of MAS are fully 
reversible. The treatment consists of:
 — hospitalisation with the aim of monitoring treat-
ment;
 — elimination of causative factors (e.g. discontinuing 
potentially nephrotoxic drugs);
 — temporary cessation of calcium and vitamin D sup-
plementation;
 — intravenous crystalloid infusion, in case of an exces-
sively positive fluid balance and symptoms sugges-
tive of congestive heart failure. Forced diuresis using 
loop diuretics may be necessary;
 — there is currently no foundation for the routine ad-
ministration of glucocorticosteroids in hypercalcae-
mia caused by MAS. Their favourable mechanism 
of action is based on the inhibition of calcitriol 
synthesis by granulomatous cells or other cells pos-
sessing PTH­independent alpha­hydroxylase. The 
active vitamin D metabolite in MAS is exogenous 
in nature;
 — administering bisphosphonates in hypercalcaemia 
caused by MAS is controversial. Coexisting distur-
bances in kidney function, especially those of an ad-
vanced nature, are a contraindication. Additionally, 
the hypothesised mechanism of MAS pathogenesis 
does not justify antiresorptive therapy;
 — treatment with calcitonin causes an increase in the 
excretion of calcium by the kidneys. Therefore, it 
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may be potentially useful in treating MAS-related 
hypercalcaemia. However, the exact mechanism of 
action of calcitonin on renal function is still unclear 
and requires further investigation [17].
Conclusions
1.  Milk-alkali syndrome (MAS) may occur at any stage 
of hypoparathyroidism.
2.  Common triggering factors are dehydration, a ve-
getarian (alkaline) diet, and treatment with thiazide 
diuretics.
3.  In order to make an early diagnosis of milk-alkali 
syndrome, it is necessary to routinely monitor 
calcium, phosphate, and creatinine concentrations 
in patients being treated for hypoparathyroidism.
4. Rapid resolution of tetany symptoms requires spe-
cial attention, as well as other cases of unexplained 
recession of hyperphosphataemia (especially in the 
absence of dietary modifications).
5. Metabolic alkalosis is a late symptom of MAS and 
is frequently preceded by impaired renal function.
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